HEALTH

• A new study from the University of Southern California (USC) is investigating the causes of lung cancer in healthy, young non-smokers, specifically examining if certain healthy foods may carry unexpected risks. • Separate research highlights a critical link between adequate sleep and weight management, suggesting that poor sleep habits increase the risk of obesity-related conditions. • These findings emphasize that sleep quality is as essential as diet and exercise in preventing chronic diseases.

• Clinicians in southeast Michigan and northern Ohio are reporting a surge of gastrointestinal illnesses caused by the parasite Cyclospora cayetanensi. • The outbreak is characterized by sudden, explosive diarrhea, though the CDC is reportedly lagging in its tracking and response efforts. • Acting CDC Director Jay Bhattacharya has addressed staff via internal email regarding the agency's response to the outbreak.

• Cyclosporiasis is classified as a nationally notifiable disease, requiring cases to be reported to the CDC to monitor public health trends. • The CDC, in coordination with state and federal regulatory officials, conducts year-round surveillance to identify outbreaks linked to common food sources in the U.S. • Due to a recent increase in cases, the CDC has committed to publishing updated surveillance data more frequently than in previous seasons.

• Health news reports are highlighting a current outbreak of cyclosporiasis, a parasitic infection that causes severe diarrhea. • The reports also address the consequences following the expiration of Affordable Care Act (ACA) subsidies and issues involving the FDA CBER acting director. • These updates matter as they track public health threats and the accessibility of healthcare coverage for affected populations.

• The FDA has introduced a new fast-track program for the approval of biologics, including experimental gene therapies for conditions like sickle cell disease and cancer. • Traditionally, the agency requires a rigorous three-phase trial process involving healthy volunteers, dose-finding studies, and large-scale clinical trials to ensure safety. • Critics argue that these political shortcuts may undermine the FDA's international reputation and its standing as a global authority on drug safety.

• Leading researchers are warning that a recent FDA policy shift may lead to the approval of ineffective medicines. • In February, the FDA announced that drug sponsors could seek approval based on a single clinical trial and confirmatory evidence, departing from a 1960s-era requirement for two clinical studies. • This change is concerning to experts because it may allow drugs with conflicting trial data to enter the market, potentially compromising patient safety and efficacy.

• Congress has returned from recess to prioritize bipartisan healthcare legislation, specifically targeting prior authorization reform and the expansion of remote patient monitoring. • Key legislative goals include extending Affordable Care Act (ACA) premium tax credits to maintain insurance affordability for millions of Americans. • Regulatory updates from CMS and the FDA introduce critical changes to 340B drug pricing policies and hospital outpatient payment systems.

• Scientists have launched the EBO-PEP clinical trial to test an experimental antiviral pill designed to prevent the Bundibugyo strain of Ebola after exposure. • The study is being led by the DRC's National Institute for Biomedical Research (INRB), France's ANRS Emerging Infectious Diseases, and the medical organization ALIMA. • This research is critical because there are currently no licensed vaccines or treatments specifically for the Bundibugyo strain, leaving a gap in outbreak control.

• A public health emergency occurred in May 2026 across the Democratic Republic of the Congo and Uganda due to an outbreak of Bundibugyo virus disease. • The disease, caused by *Orthoebolavirus bundibugyoense*, is characterized by high mortality rates and a lack of understood reservoir ecology. • Current medical responses are hindered by limited diagnostic implementation and a total absence of licensed vaccines or therapeutics specifically approved for this species.

• The free-market policy group Unleash Prosperity released a report arguing that significant reforms to the FDA could unlock trillions of dollars in economic value. • The report specifically targets the FDA's lengthy approval process, focusing on the excessive years spent proving a drug's efficacy rather than just safety testing. • This initiative matters because reducing bureaucratic delays in drug approval could accelerate patient access to life-saving treatments and stimulate pharmaceutical innovation.

• A multistate outbreak of cyclosporiasis has been identified across the United States, though the specific source of the contamination remains unknown. • Health officials are urging individuals to report all suspected cases of the parasitic infection to their local health departments to assist in tracking. • The situation is critical as identifying the source is necessary to prevent further infections and provide guidance on patient management.

• A study published in BMC Infectious Diseases tracking 724 US participants reveals that flu symptoms can linger for up to a month, challenging the perception of influenza as a short-lived illness. • While severe symptoms typically fade within days, the research highlights a significant period of recovery where nagging effects persist for several weeks. • These findings are critical for understanding post-viral recovery and may provide parallels for treating the 1% to 5% of adults worldwide suffering from long COVID.

• The CDC confirmed 843 cases of Cyclospora across 31 states as of July 9, 2026, while a separate, larger outbreak in Michigan has surpassed 1,562 reports. • Health officials have not yet identified a specific food source responsible for the infections, though the outbreak persists through the summer season. • This situation is critical as it requires urgent medical attention for severe dehydration and specific antibiotic treatment, such as trimethoprim-sulfamethoxazole.

• The CDC, FDA, and local health departments are investigating multistate outbreaks of domestically acquired cyclosporiasis across the U.S. in 2026. • Officials are working to identify the specific food or water sources causing the infections, noting that the actual number of cases is likely higher due to underreporting. • This health advisory provides critical guidance to clinicians and laboratorians to improve the recognition, diagnosis, and reporting of the parasite.

• NanoViricides has received approval from the National Ethics Committee in the Democratic Republic of Congo to conduct a Phase II trial of NV-387. • The trial will test the efficacy of NV-387 oral gummies specifically designed to treat the Bundibugyo strain of the Ebola virus. • The company is now preparing the necessary regulatory filings for ACOREP to move the clinical study forward.

• Sanofi's stock price has remained steady as of July 13, 2026, reflecting the company's stable market position within the global pharmaceutical industry. • The company's long-term growth is supported by a diversified portfolio that includes prescription medicines, vaccines, and consumer health products. • This stability is driven by consistent global demand for healthcare services, providing a reliable foundation for long-term investors.

• Researchers from the University of Adelaide found that intermittent fasting is as effective for weight loss as traditional calorie restriction. • An 18-month clinical trial involving over 200 adults with obesity demonstrated that fasting requires significantly less mental effort than constant calorie counting. • Published in Clinical Nutrition, the study suggests fasting provides a more practical and sustainable alternative for individuals struggling with restrictive dieting.

• Oxford University has launched Phase 1 human trials for a new Ebola vaccine targeting the Bundibugyo strain, supported by CEPI. • The Serum Institute is producing over 620,000 doses, with the trial beginning just 57 days after the WHO declared the outbreak a Public Health Emergency of International Concern. • This rapid development marks one of the fastest responses to an emerging infectious disease, aiming to curb the spread of the rare strain.